A decade of benchwork and clinical observations have yielded profound insight into psoriasis and the inflammatory and immunologic pathways.1 These new insights have produced exciting new and potentially rewarding therapies for dermatology.2 Much of the recent dermatology literature on new therapies has focused on large molecules, protein-based fusion proteins, and monoclonal antibodies; however, other compounds have not been neglected. Paralleling their larger relatives, small molecules are in development with numerous new agents directed at potential therapeutic targets. This article briefly reviews biologic and small molecule moieties that have potential application in the treatment of psoriasis. A few of the drugs are currently marketed though not yet indicated for psoriasis while others exist in preclinical and early clinical development.

Much of the recent dermatology literature on new therapies has focused on large molecules, protein-based fusion proteins, and monoclonal antibodies; however, other compounds have not been neglected.